Crispr Therapeutics AG vs iShares Semiconductor ETF — how do they compare? Crispr Therapeutics AG trades at $53.6 (market cap $4.88B), while iShares Semiconductor ETF trades at $559.1 (market cap $48.19B). The key difference: iShares Semiconductor ETF is far larger — about 9.9× Crispr Therapeutics AG's market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares Semiconductor ETF for 46 Days on average.
| CRSP | SOXX | |
|---|---|---|
Market Cap | $4.88B | $48.19B |
Volume | 2,861,747 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $74.92 | $655.01 |
52-Week Low | $44.34 | $268.10 |
Typical Hold Time | 77 Days | 46 Days |
Enterprise Value | $3.30B | — |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
SOXX trades at $559.40, down 4.04% over the past 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The semiconductor ETF faces mixed sentiment with strong AI-driven earnings growth projections but concerns about valuation premiums. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.33 dividend payment in September 2026.
The outlook remains cautiously optimistic with AI infrastructure demand driving earnings growth, though high valuations and bearish bets from notable investors like Michael Burry present significant risks. Wall Street analysts maintain positive ratings based on semiconductor market expansion projections, with Bank of America forecasting near-doubling of the global chip market by 2030.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →